Description:
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
Recruiting
Phase 2
Drug | Synonyms | Arms |
---|---|---|
Descartes 11 | Descartes 11 |
Name | Type | Description | Interventions |
---|---|---|---|
Descartes 11 | Experimental |
|
Inclusion Criteria: - Patients must be 18 years of age or older at the time of enrollment - High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs). Exclusion Criteria: - Patients who are pregnant or lactating. - Patients who have any active and uncontrolled infection. No blood cultures are necessary unless clinically indicated.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Measure: | Rate of stringent complete response |
Time Frame: | 2 years |
Safety Issue: | |
Description: |
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Cartesian Therapeutics |
February 10, 2021